


Ibrutinib, the first available BTK inhibitor: single center experience

Ann Janssens, Vibeke Vergote, Hélène Schoemans, Mariëlle Beckers, Timothy Devos, Daan Dierickx, Michel Delforge, Johan Maertens, Gregor Verhoef, Peter Vandenberghe, Department of Hematology, UZ Leuven, Leuven, Belgium

Since January 2013 we treat patients with CLL, MCL and WM with ibrutinib, first in clinical trials and later as a reimbursed treatment option. Till now, this oral treatment is given till intolerance or disease progression. As responses are durable and treatment well tolerated, treatment duration is expected to be long and consequently costly for the community. We wondered how long we treat patients with ibrutinib in daily clinical practice and why treatment has to be discontinued.



Although ibrutinib is well tolerated, adverse events are the most common reason of discontinuing treatment in CLL as progressive disease is the most important reason of holding drug in MCL.

In our cohort, 37% (34/92) had stopped ibrutinib 12mo after the start.